MAK 683

Drug Profile

MAK 683

Alternative Names: MAK-683

Latest Information Update: 11 Nov 2016

Price : $50

At a glance

  • Originator Novartis
  • Class Antineoplastics
  • Mechanism of Action Protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Lymphoma; Solid tumours

Most Recent Events

  • 01 Oct 2016 Phase-I/II clinical trials in Lymphoma (Late-stage disease, Metastatic disease, Recurrent) in USA (unspecified route) (NCT02900651)
  • 01 Oct 2016 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Recurrent, Metastatic disease) in USA (unspecified route) (NCT02900651)
  • 02 Sep 2016 Preclinical trials in Lymphoma (Late-stage disease, Recurrent, Refractory metastatic disease) in USA (unspecified route) before September 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top